A newly formed corporate VC of a pharmaceutical company is investing from an evergreen fund. The firm is interested in investing in companies in therapeutics, AI/ML drug discovery tools, digital therapeutics, virtual care platforms and connected devices. For therapeutics companies, the firm prefers to invest in companies that are preclinical, before IND. For other companies, the firm prefers to invest close to revenue, post pilot. The firm invests in companies based in North America, Europe and Israel from pre-seed to Series A, and will invest between .5-4M EUR in their first round, with capital reserved for follow on investments.
Historically, the firm has focused on CNS disorders and rare diseases, including areas such as neurodevelopment, epilepsy and mental health. The firm is investing in this area, with an additional focus on pregnancy, childbirth and women’s health.
The firm takes at minimum a board observer seat when investing, and look to help the company strategically with their expertise and network.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Newly Formed Corporate VC Arm of Pharma Seeks to Invest in Therapeutics, Drug Discovery Tools, and More in CNS and Rare Diseases
26 JanHot Investor Mandate: VC/PE Firm Based in the US Invests Up to $15M With Strongest Interests in Therapeutics, and Platform Technologies
26 JanA venture capital/private equity firm based in the US invests in both digital health technologies and the life sciences. For their life sciences investments, most of them are in therapeutics, with about 5% of their investments going to life science tools and diagnostics. For therapeutics companies, the firm prefers to see efficacy and safety data before investing. For tools, diagnostics and digital health companies, the companies should be either revenue generating, or, at minimum, revenue in sight. The firm will consider global opportunities, but invests primarily in the US, and generally invests 5-15M in their early stage deals.
For therapeutics companies, the firm is modality and indication agnostic, although is less interested in microbiotic-related therapeutics. The firm prefers platform technologies, or an associative program; they do not invest in single assets. For digital health companies, the firm invests primarily in enterprise software, such as clinical data management, tools to enable better care and healthcare IT companies.
The firm generally leads or co-leads investments, and will take a board seat after investing. For therapeutics companies, the firm prefers the startups to have raised 1-5M in a previous round before investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Active VC Firm With Over 200 Portfolio Companies Invest Mainly in Digital Health and Technologies Leveraging AI, Big Data, and More
26 JanA venture capital firm focuses its investments on data moat and network effect. The firm currently manages over $1B AUM and since inception, has invested in over 260 companies from seed to growth stages and continues to seek investment opportunities across the globe.
Within life sciences and healthcare, the firm invests in digital health and technologies that leverage AI, big data, and other applications in the intersection of science and technology. While the firm does not typically invest in traditional therapeutics, but has invested in medical device and diagnostic companies in the past. In terms of stage of development, the firm is open to the earliest stages of development and is agnostic towards indication area.
The firm seeks to work with dedicated, experienced management teams. The firm is open to working with first time entrepreneurs, and often acts as the first institutional investor. The firm is open to either acting as a lead or co-investor, and seeks board representation when leading.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Investment Arm of Asia-Based Pharmaceutical Company Seeks Equity Investment and In-Licensing Opportunities in Novel Therapeutic Modalities
26 JanA pharmaceutical company headquartered in Asia has 40 branches and subsidiaries around the world (including the United States, Japan, Germany, Russia, Spain, India, etc.). The firm’s main business covers chemical and biological medicines, pharmaceutical packaging, and trading.
The firm’s investment subsidiary is responsible for equity investment and in-licensing activities for its corporate parent.
The firm is most interested in companies developing novel drugs in Biologics, Cell therapy, Gene therapy, Repurposed drugs, and Biosimilars. The firm is interested in distribution rights in China. In terms of stage of development, companies that are at or before the NDA stage are preferred (Pre-clinical, Phase I, Phase II, Phase III, NDA).
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Congratulations to the RESI JPM San Francisco Pitch Winners!
19 JanBy Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
At RESI JPM San Francisco, we had over 50 companies participate in the Innovator’s Pitch Challenge (IPC). These finalist companies pitched to an audience and judging panel, as well as exhibited a poster showcasing their technology.
Registered RESI attendees (startup executives, early-stage investors and industry experts), vote for their favorite IPC company based on the pitch company’s poster board displayed at RESI’s exhibit hall and their performance in the Q&A portion of their pitch session.
Life Science Nation is pleased to share the winners who received the most votes during the RESI JPM San Francisco. Congratulations to the winners!
First Place: Field Orthopaedics
“Quick Procedure, Fast Recovery. We Nailed Hand Fractures”. Field Orthopaedics (FO) is a revenue stage Australian medical device company operating in the Orthopaedics Devices Market, dedicated to innovating and delivering best in class medical implants and solutions to advance extremity surgery, specifically targeting the hand and wrist market. We reimagine an underserviced extremity segment which traditionally experienced limited innovations and fragmented approaches to solving clinical problems, leading to lower complication rates and better patient outcomes. At FO, we bring together ideas & innovations to build what Hand surgeons want and get patients to activity faster. We are at the forefront to re-invent orthopaedic hand surgery.
Patryk J Kania, CEO of Field Orthopaedics
Second Place: CytoAurora Biotechnologies, Inc.
CytoAurora is developing single-cell technology and focusing on Diagnostic and CDMO application platforms. Our mission is to build a world-leading bio-company through a unique integration of Taiwan”s semiconductor, A.I. technology, precision machinery, and biomolecular technology. We developed a “Cell Reveal system,” IVD certified by TFDA and NMPA for performing rare circulating tumor cell detections in precision medical applications. CytoAurora has over 20 patents in various fields, such as semiconductor biochip and artificial intelligence systems. We insist on our technology, independent innovation, and sustainable invention. Moreover, we can select specific cells for gene amplification and analysis for future research. As the leader in single-cell technology, CytoAurora also provides robust and customized equipment in rapid drug screening, single-cell selections, cell therapy applications in the pharma market.
Chung- Er Huang (CE), CEO and founder of CytoAurora Inc.
Third Place: Max Kelsen
Max Kelsen is an award winning artificial intelligence and digital health solutions company supporting healthcare and life sciences institutions globally throughout the full product lifecycle from research and ideation, regulatory and market access planning through to end-to-end product development and post market surveillance. Max Kelsen has a proven track record in developing and translating clinical data platforms, companion applications, software as a medical device and digital therapeutics in partnership with healthcare providers and researchers as well as world renowned medical device manufacturers. In 2020, MK was a partner of the year for both Google Cloud (GC) and Amazon Web Services (AWS), was named in Deloitte”s technology fast 50 and was recently recognized as Google Cloud”s Healthcare Partner of the year.
Miriam Kent, General Manager of Brisbane Economic Development Agency
(Accepting on behalf of Max Kelsen a member of the BEDA group)
If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the Digital RESI IPC taking place March 14-16 with a 3-day virtual conference. Applications are accepted on a rolling basis, so get your application submitted today!
Digital RESI March registration opens at super early bird rates. Register now to save $300 by Friday, January 27.
RESI JPM San Francisco 2023 Program Guide
5 JanBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
2023 kicks off Life Science Nation’s 10th Anniversary. This celebratory year begins with our first conference of the year, RESI JPM San Francisco, next week, January 10 in person and January 11-12 virtual! This hybrid conference will take place at the Marines’ Memorial Club & Hotel in San Francisco, and we are excited to release the digital RESI Program Guide. Check out the variety of panelists, exhibitors and workshops participating in this RESI. In addition, make sure to check out the Innovator’s Pitch Challenge, where over 50 companies will pitch to a panel of investor judges.
We look forward to seeing you at RESI next week! You can still register for the conference and begin to book meetings in partnering today.
Hot Investor Mandate: Global Investment Firm Invests Up to $40M in Early Clinical Stage Therapeutics, Medical Devices, and Diagnostics Companies
5 JanA global investment firm with bases in USA and Asia is primarily focused on healthcare investments and looks to make allocations ranging from $1M to $40M depending on opportunity and risk/reward. The firm is actively seeking new investments and is open to review opportunities from around the globe.
Within the life science space the firm is interested in Therapeutics, Medical Devices, and Diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.
The firm is open to investing in both private and publicly held companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 